Abstract | BACKGROUND: PATIENTS AND METHODS: Fourteen KS patients were studied; 12 were in the poor-risk group. At given intervals, the patients underwent clinical examination, and their CD4(+) cell counts, plasma HIV-1 RNA levels, and antibody titers to lytic-phase ORF65 and latent-phase HHV8 proteins were determined. RESULTS: When last seen, the overall clinical response rate was 86% (median follow-up, 22 months); 10 complete and two partial responses were achieved, and two patients showed disease progression. All patients with complete or partial response showed a consistent decrease in HIV-1 RNA levels, with a corresponding increase in CD4(+) cell counts; HIV-1 RNA levels in the two progressors remained persistently high, despite a change in HAART. HHV8 ORF65 antibody titers were generally higher in patients with extensive skin or mucosal/visceral involvement versus patients with limited disease; no differences in latent-phase HHV8 antibody titers were observed in relation to tumor burden. CONCLUSION: The findings indicate that antiretroviral therapy with protease inhibitors is effective for AIDS-related KS; the clinical response was correlated with a decrease in plasma HIV-1 RNA levels and an increase in CD4(+) lymphocytes, whereas antibody levels to the lytic-phase HHV8 protein were influenced by the extent of tumor involvement.
|
Authors | A M Cattelan, M L Calabrò, P Gasperini, S M Aversa, M Zanchetta, F Meneghetti, A De Rossi, L Chieco-Bianchi |
Journal | Journal of the National Cancer Institute. Monographs
(J Natl Cancer Inst Monogr)
Issue 28
Pg. 44-9
( 2001)
ISSN: 1052-6773 [Print] United States |
PMID | 11158206
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Antibodies, Viral
- Antiviral Agents
- HIV Protease Inhibitors
- RNA, Viral
- Reverse Transcriptase Inhibitors
|
Topics |
- Acquired Immunodeficiency Syndrome
(complications, drug therapy)
- Adult
- Anti-HIV Agents
(therapeutic use)
- Antibodies, Viral
(blood)
- Antiretroviral Therapy, Highly Active
- Antiviral Agents
(therapeutic use)
- CD4 Lymphocyte Count
- Disease Progression
- Drug Evaluation
- Follow-Up Studies
- HIV Protease Inhibitors
(therapeutic use)
- HIV-1
(isolation & purification)
- Herpesvirus 8, Human
(immunology)
- Humans
- Male
- Middle Aged
- Mucous Membrane
(pathology)
- Prospective Studies
- RNA, Viral
(blood)
- Remission Induction
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Sarcoma, Kaposi
(blood, drug therapy, etiology, pathology, virology)
- Skin Neoplasms
(blood, drug therapy, etiology, pathology, virology)
- Soft Tissue Neoplasms
(blood, drug therapy, etiology, pathology, virology)
- Treatment Outcome
- Viral Load
- Viremia
(drug therapy, virology)
- Viscera
(pathology)
|